TRANSLATIONAL RESEARCH ETHICS

The purpose of translational research is to test novel therapeutic strategies and drugs throughout basic and clinical research. The basic concept of translational research is ‘Bench to Bedside’, defining the collaboration between clinicians and basic scientists. That means translational research involves synergistic partnerships between industry, foundations, and public health services. The collaboration between partners provides a network structure that uses multiple methods and technologies to harmonize parameters such as complexity, expertise, safety, and efficiency with national regulations, institutional policies, and best practices that govern cell, animal, and human research. One might think that the ethics of translational research is simple because there are extensive rules regarding basic and clinical research ethics. Nevertheless, translational research brings new tools to the scene such as employing biomarkers based on omics technology and genomics. On the other hand, data science using real-world data, big data, data mining, and artificial intelligence is another huge leverage for translational research bringing new ethical and legal issues, especially concerning data protection. Therefore, new ethical issues arise that have not been addressed before. As the name reflects, translational research ethics should be considered as the means of a literal translation as well. Ethics should serve to translate the language used by different disciplines and moreover by all stakeholders including social areas from the public to the governmental bodies etc. to translate these different languages and attitudes to each other and make the science more transparent and reliable.

TRANSLATIONAL RESEARCH ETHICS

The purpose of translational research is to test novel therapeutic strategies and drugs throughout basic and clinical research. The basic concept of translational research is ‘Bench to Bedside’, defining the collaboration between clinicians and basic scientists. That means translational research involves synergistic partnerships between industry, foundations, and public health services. The collaboration between partners provides a network structure that uses multiple methods and technologies to harmonize parameters such as complexity, expertise, safety, and efficiency with national regulations, institutional policies, and best practices that govern cell, animal, and human research. One might think that the ethics of translational research is simple because there are extensive rules regarding basic and clinical research ethics. Nevertheless, translational research brings new tools to the scene such as employing biomarkers based on omics technology and genomics. On the other hand, data science using real-world data, big data, data mining, and artificial intelligence is another huge leverage for translational research bringing new ethical and legal issues, especially concerning data protection. Therefore, new ethical issues arise that have not been addressed before. As the name reflects, translational research ethics should be considered as the means of a literal translation as well. Ethics should serve to translate the language used by different disciplines and moreover by all stakeholders including social areas from the public to the governmental bodies etc. to translate these different languages and attitudes to each other and make the science more transparent and reliable.

___

  • Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2012;109(15):276-81
Sağlık Bilimlerinde İleri Araştırmalar Dergisi-Cover
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2018
  • Yayıncı: İstanbul Üniversitesi
Sayıdaki Diğer Makaleler

S-100 PROTEIN EXPRESSION LEVELS AS A POTENTIAL PROGNOSTIC MARKER IN NEUROBLASTOMA

Gamze SANLAV, Burçin BARAN, Deniz KIZMAZOĞLU, Selen KUM ÖZŞENGEZER, Safiye AKTAŞ, Zekiye ALTUN, Nur OLGUN

PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING

Tekincan Çağrı AKTAŞ, Deniz KIZMAZOĞLU, Safiye AKTAŞ, Özde Elif GÖKBAYRAK, Emre ÇEÇEN, Dilek İNCE, Zekiye ALTUN, Nur OLGUN

DIETARY-BASED MOLECULAR TARGETS AND THERAPEUTIC OPPORTUNITIES IN CANCER

Gizem ÇALIBAŞI KOÇAL

REAL WORLD EVIDENCE AND BIG DATA

Mehmet Güven GÜNVER

WHEN MEIS IS UP IN PROSTATE CANCER, THEN MEISi?

Birkan GİRGİN, Dilek TELCİ, Yurdanur SÜLLÜ, Kaan OZTURK, Fatih KOCABAS

PRECISION ONCOLOGY-BASIC TO BEDSIDE

Amit VERMA

METHYLATION AND EXPRESSION VALIDATION RESULTS OF GPRC5C GENE OBTAINED FROM EPIGENOMICS AND TRANSCRIPTOMICS DATA IN ORAL CAVITY TUMORS

Gizem ESENTÜRK, Can DORUK, Murat ULUSAN, Nejat Vakur OLGAÇ, Semra DEMOKAN

INVESTIGATION OF THE EXPRESSION LEVEL OF miR 142-3P IN OVARIAN CARCINOMA

Yasemin GIDER, Khariqa JABBARLİ, Gamze UYAROĞLU, Demet AKDENİZ ÖDEMİŞ, Buğra TUNCER, Büşra KURT, Seda KILIÇ ERCİYAS, Özge ŞÜKRÜOĞLU ERDOĞAN, Betül ÇELİK, Hülya YAZICI

THE EFFECT OF SILENCING THE Tip60 GENE ON THE RESPONSE TO RADIOTHERAPY IN BREAST CANCER CELLS

Ece MİSER SALİHOĞLU, Bensu KARAHALİL, Sevgi AKAYDIN

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Semra DEMOKAN, Sena SEN, Onder ERYILMAZ, Sevde COMERT, Murat ULUSAN, Mehmet Nejat DALAY